Cytonics has received over $25M in funding to date, including $1.8M from the National Institute of Health and a $4M investment from Synthes (a Johnson and Johnson company). Now, we are raising capital from both non-accredited and accredited investors to advance our novel osteoarthritis treatment, CYT-108, through human clinical trials.
To learn more about how you can become a shareholder, please visit invest.cytonics.com.
Reg A Disclaimer: This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
